Sylvester Comprehensive Cancer Center

  • 20231360 - Beitinjaneh Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:

    IRB: 20231360

    SDG: Cellular Therapy
    Disease Site(s):

    Hodgkin Lymphoma,Non-Hodgkin Lymphoma

    Sponsor: Indiana University

    Enrolling Sites:

    Coral Springs
    Gables
    Plantation
    Sylvester
    UMH

    Title:

    A Phase I, Multicenter Study of CD4- directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with Relapsed or Refractory CD4+ Lymphoid Hematological Malignancies

    Eligibility Criteria - NCT03829540 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220984 - Hernandez Aya Leonel

  • Investigator:
    Leonel Hernandez Aya
    RCname Email

    Coordinator:

    IRB: 20220984

    SDG: Cellular Therapy
    Disease Site(s):

    Multiple

    Sponsor: Immatics US Inc

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine IMA203-101)

    Eligibility Criteria - NCT03686124 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230190 - Jimenez Antonio

  • Investigator:
    Antonio Jimenez
    RCname Email

    Coordinator:

    IRB: 20230190

    SDG: Cellular Therapy
    Disease Site(s):

    Leukemia, not otherwise specified

    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH

    Title:

    A Phase 1 Study of Venetoclax in Combination with Azacitidine (VEN/AZA) followed by Donor Lymphocyte Infusion (DLI) for Patients with Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

    Eligibility Criteria - NCT06158100 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231336 - Jimenez Antonio

  • Investigator:
    Antonio Jimenez
    RCname Email

    Coordinator:

    IRB: 20231336

    SDG: Cellular Therapy
    Disease Site(s):

    Leukemia, not otherwise specified,Non-Hodgkin Lymphoma

    Sponsor: NATIONAL MARROW DONOR PROGRAM

    Enrolling Sites:

    Coral Springs
    Gables
    Plantation
    Sylvester
    UMH

    Title:

    A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

    Eligibility Criteria - NCT06001385 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210828 - Lekakis Lazaros

  • Investigator:
    Lazaros Lekakis
    RCname Email

    Coordinator:

    IRB: 20210828

    SDG: Cellular Therapy
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    UMH

    Title:

    ML43165 - Single Arm Phase 2 Trial of an FDA Approved anti-CD19 CAR-T Therapy followed by Mosunetuzumab and Polatuzumab Consolidation for the Treatment of Refractory/Relapsed Aggressive NHL

    Eligibility Criteria - NCT05260957 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240912 - Lekakis Lazaros

  • Investigator:
    Lazaros Lekakis
    RCname Email

    Coordinator:

    IRB: 20240912

    SDG: Cellular Therapy
    Disease Site(s):

    Brain and Nervous System

    Sponsor: Juno

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH

    Title:

    A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy or Systemic Sclerosis

    Eligibility Criteria - NCT05869955 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210661 - Pereira Denise

  • Investigator:
    Denise Pereira
    RCname Email

    Coordinator:

    IRB: 20210661

    SDG: Cellular Therapy
    Disease Site(s):

    Multiple Myeloma,Other Hematopoietic

    Sponsor: CELGENE

    Enrolling Sites:

    Sylvester

    Title:

    EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE

    Eligibility Criteria - NCT04771078 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240449 - Pereira Denise

  • Investigator:
    Denise Pereira
    RCname Email

    Coordinator:

    IRB: 20240449

    SDG: Cellular Therapy
    Disease Site(s):

    Brain and Nervous System

    Sponsor: Kyverna Therapeutics Inc

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH

    Title:

    A Phase 2, Open-Label, Multicentre Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Generalized Myasthenia Gravis (KYSA-6)

    Eligibility Criteria - NCT06193889 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230616 - Spiegel Jay

  • Investigator:
    Jay Spiegel
    RCname Email

    Coordinator:

    IRB: 20230616

    SDG: Cellular Therapy
    Disease Site(s):

    Multiple Myeloma

    Sponsor: Caribou Biosciences

    Enrolling Sites:

    Gables
    Plantation
    Sylvester

    Title:

    A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)

    Eligibility Criteria - NCT05722418 *This information has been extracted from " www.clinicaltrials.gov"

  • CCTL019B20031 - Wang, Trent

  • Investigator:
    Trent Wang
    RCname Email

    Coordinator:

    IRB: 20190006

    SDG: Cellular Therapy
    Disease Site(s):

    Lymphoid Leukemia,Non-Hodgkin Lymphoma

    Sponsor: NOVARTIS

    Enrolling Sites:

    Sylvester

    Title:

    CCTL019B2003I: Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

    Eligibility Criteria - NCT03601442 *This information has been extracted from " www.clinicaltrials.gov"